Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.
Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.
Orladeyo, a capsule taken daily to prevent attacks, is the revenue base; it is sold mainly in the US through specialty pharmacies, with overseas partners selling in some markets. Because patients stay on it for years, revenue recurs, and some proceeds are owed to outside royalty holders from earlier financing.
Moat: narrow (regulatory licence, IP / patents). Approved oral HAE prophylaxis with growing sales, though competing against injectable alternatives.
Headquarters: Durham, North Carolina, US · Founded: 1986 · Employees: 435
Size BioCryst Pharmaceuticals (BCRX) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1807th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.30 on 18 Nov 2026.
Performance Over six months the shares fell 16.5%, against -3.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.
Growth Revenue grew 60.3% over the last twelve months (peer median +5.5%); the operating margin is 42.5% (peer median -58.6%).
Valuation It trades at 11.1× forward earnings against a peer median of 51.9× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +118%, so the hurdle is -129 pp: the price already allows for a slowdown.
Short interest Short interest is 10.7% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $962M | $875M | $451M | $331M | $271M |
| Revenue growth | — | +94% | +36% | +22% | — |
| Gross profit | $939M | $854M | $437M | $325M | $263M |
| EBITDA | $411M | $342M | -$1.30M | -$102M | -$147M |
| Net income | -$360M | $264M | -$88.9M | -$227M | -$247M |
| Free cash flow | $349M | $327M | -$53.1M | -$97.3M | -$163M |
| Capital expenditure | $1.65M | $2.47M | $1.12M | $2.17M | $1.35M |
| Total debt | $828M | $477M | $841M | $849M | $741M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals BCRX | $1.88B | -16% | +60% | 42% | 11.1× | -11.0% |
| Pharvaris PHVS | $2.21B | +7% | n/a | n/a | n/a | n/a |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | n/a | n/a |
| Intellia Therapeutics NTLA | $1.37B | -20% | -8% | -821% | n/a | n/a |
| Pharming PHARM.AS | $867M | -6% | +2% | 9% | 34.9× | 2.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BCRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.1% | -1.1% | 7th lowest of 20 |
| 6-month return | -16.5% | -3.6% | 6th lowest of 19 |
| Distance from 52-week high | -34.9% | -33.4% | 10th lowest of 21 |
| Revenue growth (TTM) | +60.3% | +5.5% | 3rd highest of 15 |
| Operating margin | 42.5% | -58.6% | 2nd highest of 15 |
| Forward P/E | 11.1× | 51.9× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -11.0% | 13.1% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +117.9% | +19.9% | highest of 5 |
| Hurdle (Req g minus delivered) | -128.9 pp | -9.5 pp | least demanding of 5 |
| EV / EBITDA | 5.7× | n/a | — |
| Net debt / EBITDA | 1.1× | -2.6× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 11.1× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 105.5× | 22.7% | +3.4% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 18.1× | 3.5% | +41.4% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 126.7× | n/a | n/a |